-
Electronic (PDF)
-
Site License
-
Enterprisewide
Accountable Care Organizations - A Building Block for the Future of Health Care
CBR Pharma Insights, August 2012, Pages: 53
The Accountable Care Act promoted ACOs through a variety of programs: Comprehensive Primary Care Initiative, Partnerships for Patients Initiative, Pioneer and Advanced Payment ACO Models and Medicare Shared Savings Program for ACOs. The central program is the Medicare Shared Savings Program, under which ACOs gradually share in the cost savings they achieve through providing coordinated and consistent care to groups of Medicare beneficiaries while meeting quality targets.
The focus of ACOs is coordinated care, ease-of-access, care management models, evidence-based care, technology use for data management, and clinical integration. This may mean some changes for pharmaceutical companies looking to work with ACOs. Promotional materials will need to highlight evidence-based medicine findings and detailing should highlight potential cost efficiencies. Patient outreach aspects of ACOs will give pharmaceutical companies an opportunity to provide patient educational materials.
The report, “Accountable Care Organizations - A Building Block for the Future of Health Care” has been written to support corporate strategy, managed markets, business insights, and product strategy teams through its analysis of the changes taking place in the health care landscape and the impact ACOs will have on the way patients are treated. As an integral part of Health Care Reform in the US, pharmaceutical companies must understand how ACOs will work, and in turn, affect their current and future business.
Key Reasons to Purchase
- Understand the final rules for the government’s ACO programs
- Analyze the ways ACOs may impact pharmaceutical promotional activities
- Gain insights through the examination of cases study analysis of the potential for ACOs to bring reform forward
- Understand the challenges ACOs face now and in the future
- Assess the opportunities ACOs can bring to pharmaceutical companies
Executive Summary
Chapter 1: Development of ACOs
- Background
- Health care reform of 2010
- ACO Programs
- Comprehensive Primary Care Initiative
- Partnerships for Patients Initiative
- Pioneer and Advance Payment ACO Models
- Medicare Shared Savings Program
- Final rules
Chapter 2: Health care community response
- Physician response
- Patient response
Chapter 3: Case Studies
- Case study one: better rates for breast cancer screening through coordinated teams
- Case study two: easier neurological care with a simple change
- Case study three: finding more cost-effective ways to treat mental health
- Case study four: decreasing infections through evidence-based care
- Case study five: using technology to help care for heart disease patients
- Case study six: improving Diabetes outcomes with a care management model
Chapter 4: What ACOs mean for pharmaceutical companies
- Evidence-based medicine and promotion
- Changes for detailing
- Educational materials for patients
- Educational programs for physicians
- Opportunities for growth
Chapter 5: What ACOs won’t do
- Large scale change might not be achievable
- Hospitals rather than doctors may be empowered
- Patients may reject the model
- The test run of the ACO model was not a clear success
Chapter 6: The outlook for ACOs
- The Supreme Court decision
- The November elections
- Electronic health records
- Data management
Appendix
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
